Loading clinical trials...
Loading clinical trials...
The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.
All patients diagnosed with breast cancer who meet the eligibility criteria at participating centers will be included. Data will be collected from medical records at selected centers. Data collection will start from the location activation date. Data from up to 500 patients are expected to be collected at centers across Brazil. Patients recruited for this study will be identified at participating centers. Data on clinical, demographic and socioeconomic variables will be collected, as well as data on treatments performed and outcomes. The patient data sources will be the patients' medical records. Patients will continue to receive treatment and clinical evaluations for their illness as determined by their medical team, in accordance with the standards of care and usual clinical practice at each center. No intervention is proposed in this study.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
ICC - Instituto do Câncer do Ceará
Fortaleza, Ceará, Brazil
Hospital Sírio-Libanês DF
Brasília, Federal District, Brazil
Hospital Márcio Cunha da Fundação São Francisco Xavier (HMC-FSFX)
Ipatinga, Minas Gerais, Brazil
Oncominas - Clínica de Oncologia no Sul de Minas
Pouso Alegre, Minas Gerais, Brazil
Real Hospital Português de Beneficência em Pernambuco
Recife, Pernambuco, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, São Paulo, Brazil
Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)
Rio de Janeiro, Brazil
Hospital Sírio-Libanês SP
São Paulo, Brazil
HAOC - Hospital Alemão Oswaldo Cruz
São Paulo, Brazil
BP - A Beneficência Portuguesa de São Paulo
São Paulo, Brazil
Start Date
November 9, 2023
Primary Completion Date
June 1, 2025
Completion Date
June 1, 2025
Last Updated
March 7, 2025
400
ESTIMATED participants
Lead Sponsor
Latin American Cooperative Oncology Group
NCT06719440
NCT05775757
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06311955